KalVista Pharmaceuticals, Inc.
KALV
$19.56
-$1.30-6.23%
NASDAQ
| 12/31/2025 | 09/30/2025 | 07/31/2025 | 04/30/2025 | 01/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -2.82% | -29.20% | -40.81% | -37.06% | -44.08% |
| Gross Profit | 478.64% | 102.50% | 46.17% | 37.06% | 44.08% |
| SG&A Expenses | 99.05% | 87.57% | 153.87% | 68.65% | 185.53% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 69.17% | 37.40% | 36.68% | 13.57% | 29.53% |
| Operating Income | 70.39% | -5.91% | -33.46% | -13.57% | -29.53% |
| Income Before Tax | 71.83% | -21.09% | -43.26% | -18.89% | -52.48% |
| Income Tax Expenses | -267.14% | -- | -- | -- | -- |
| Earnings from Continuing Operations | 88.93% | -26.60% | -48.59% | -16.97% | -67.11% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 88.93% | -26.60% | -48.59% | -16.97% | -67.11% |
| EBIT | 70.39% | -5.91% | -33.46% | -13.57% | -29.53% |
| EBITDA | 71.60% | -5.78% | -33.57% | -13.54% | -29.65% |
| EPS Basic | 89.44% | -9.46% | -28.42% | 3.88% | -10.23% |
| Normalized Basic EPS | 74.35% | -4.91% | -24.10% | 2.05% | -0.32% |
| EPS Diluted | 89.44% | -9.46% | -28.42% | 3.88% | -10.23% |
| Normalized Diluted EPS | 74.35% | -4.91% | -24.10% | 2.05% | -0.32% |
| Average Basic Shares Outstanding | 4.84% | 15.65% | 15.71% | 21.69% | 51.59% |
| Average Diluted Shares Outstanding | 4.84% | 15.65% | 15.71% | 21.69% | 51.59% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |